Syndesi Therapeutics is building upon a rich legacy of research on SV2A conducted at UCB. UCB identified novel modulators of SV2A that show pro-cognitive properties in preclinical models.

With the support of our investors and other stakeholders, Syndesi's goal is to demonstrate the potential of these molecules to reduce the symptoms of cognitive impairment in patients with Alzheimer's Disease and related conditions.

Our name ‘Syndesi’ comes from the Greek for ‘connection’. We are harnessing science to improve connections on many levels.

 
 

Management Team

Jonathan.png

Jonathan Savidge, PhD
Chief Executive Officer

Jonathan has worked in the pharma and biotech arena for over 18 years, focussing on collaborative deals for the development of novel therapeutics. Most recently, he spent 4 years leading business development for the biotech company Proximagen in the UK, leading several deals including a significant collaboration with Roche on a Phase II program. He also spent 5 years with Evotec as VP Business Development executing deals on clinical phase CNS assets with Roche and Janssen. Jonathan has also worked as a business development consultant with several other biotech companies including Bicycle Therapeutics, Syntaxin (acquired by Ipsen) and ReNeuron. Jonathan has a scientific background, holding a research position at Novartis in pain research following his PhD.

Jonathan Savidge, PhD
Chief Executive Officer

John Kemp, PhD
Chief Scientific Officer

John has over 30 years of experience in neuroscience research and CNS drug discovery and development. Prior to joining Syndesi, John spent the last 6 years as Senior Director Neuroscience Discovery at Janssen leading research into novel treatments for Alzheimer’s disease. John was previously Chief Research and Development officer at Evotec, having served as CEO of the spin-out Evotec Neurosciences that raised €25M in funding. Before joining Evotec, John was head of CNS Research at Roche in Basel and a member of the Global Research Portfolio Committee and CNS Disease Area Strategic Team. He also held senior research positions in Neuroscience R&D at Merck Sharpe and Dohme in the UK. John has published over 140 peer reviewed articles, was an original member of ISI’s Most Highly Cited Researcher Database and has a particular interest and expertise in synaptic physiology.

John Kemp, PhD
Chief Scientific Officer
Charlotte.png

Charlotte Videbaek, MD DMSc
Chief Medical Officer

Charlotte has over 15 years of pharma industry experience in clinical Development in CNS, project management and strategy, the last 2 years as an external consultant supporting mostly biotech companies. Previously she held positions at H. Lundbeck A/S as VP for Corporate Project Management R&D and Head of Department of International Clinical Research Neurology. In addition, Charlotte has experience as Integrated Health Care Leader at F. Hoffmann-La Roche Ltd and as Medical Safety Expert at Novartis Pharma AG. Prior to joining the pharma industry, Charlotte gained more than 10 years of clinical experience as medical doctor specialised in Neurology.

Charlotte Videbaek, MD DMSc
Chief Medical Officer

Andrea Cesura, PhD
Head of Preclinical Development

Andrea is a pharmacologist and neuroscientist with 30 years of experience in CNS research, drug discovery and development. He spent more than 10 years at Evotec as SVP of CNS Preclinical Development and then acted as Senior CNS Consultant on the steering committee on a major collaboration in Alzheimer’s Disease. Prior to joining Evotec, Andrea was a Senior Scientist and Project Leader in the CNS research department at F. Hoffmann-La Roche Ltd, and Associate Director Pharmacology at Serono. Andrea contributed to several compounds that entered clinical development, including two drugs reaching Phase 2/3 in Alzheimer’s Disease. Andrea holds a PhD in Physiological and Pharmacological Sciences from the University of Milan.

Andrea Cesura, PhD
Head of Preclinical Development
 

Board of Directors

 

Jean Combalbert, PhD
Chairman of the Board

Dr Combalbert is a successful entrepreneur with more than 20 years of experience in pharmaceutical and biotech companies. He was CEO of Ogeda (formerly Euroscreen) from 2006 until its sale to Astellas Pharma Inc. in May 2017. Prior to joining Ogeda, he was VP Pharmaceutical Development at Proteus SA, Nimes, France, then Chairman & CEO of Entomed SA, Strasbourg, France. Earlier in his career, Dr Combalbert held senior positions with Sanofi and Galderma.

Morten Graugaard Døssing, MSc
Novo Seeds

Morten joined Novo Seeds in 2016 as Investment Director. Prior to joining Novo, Morten was Director of Corporate Development at H. Lundbeck A/S where he was involved in M&A (including leading the acquisition orphan neurology company Chelsea Therapeutics), corporate strategy, BD&L, portfolio management and equity investments. He also serves on the Board of Hoba Therapeutics, Merozyne Therapeutics and NMD Pharma.

Maciek Drozdz, PhD MBA
Johnson & Johnson Innovation - JJDC

Maciek Drozdz is a Principal of Venture Investments for Johnson and Johnson Development Corporation (JJDC). Prior to JJDC, Maciek most recently served as a CEO of Antagonis Biotherapeutics, an immuno-oncology company in Graz, Austria. Previously he was investment manager at Entrepreneurs Fund LLP, investment director at MCI Bioventures and an analyst at Atlas Venture. Maciek has served on a number of boards of private and public companies across several countries.

Jean Combalbert, PhD
Chairman of the Board


Maciek Drozdz, PhD MBA
Johnson & Johnson Innovation - JJDC

Aidan King, MBA CFA
Fountain Healthcare

Aidan King is Managing Partner and co-founder of Fountain Healthcare Partners. Aidan was a founding members of Elan’s corporate venture capital group before moving to Bio-IB, a boutique life science investment bank in New York. Aidan currently sits on the boards of Chrono Therapeutics and Velicept Therapeutics. Previously, he was the firm’s representative on the boards of Civitas Therapeutics (acquired by Acorda, 2014) and Palyon Medical.

Emmanuel Lacroix, PhD MBA
UCB

Emmanuel is currently Senior Director, Venture Investments at UCB’s Corporate Venture Fund. Previously, Emmanuel was Senior Director Global Business Development at UCB, where he had responsibility for partnering and product licensing/acquisitions in Neurology. Previously in Sales & Global Marketing from 2007 to 2008, Emmanuel contributed to the coordination of global pre-launch activities for Vimpat® and the business planning for UCB’s other CNS products.

Christina Takke, PhD
V-Bio Ventures

Christina is co-founder and Managing Director of V-Bio Ventures. Before launching V-Bio Ventures, Christina was a partner at Forbion Capital Partners (previously ABN AMRO Capital) were she led and managed a series of successful investments in biopharmaceutical and pharmaceutical companies. Christina currently serves on the boards of Confo Therapeutics NV, Octimet Oncology NV and Oxular Limited.

Aidan King, MBA CFA
Fountain Healthcare


Christina Takke, PhD
V-Bio Ventures

 
 

Investors

 

Our Offices

JLABS Incubator

CEI Incubator